

**From:** Tazia Smith <[REDACTED]>  
**To:** jeevacation@gmail.com  
**Cc:** Nav Gupta <[REDACTED]>, Paul Morris <[REDACTED]>, [REDACTED], Vahe Stepanian <[REDACTED]>, Vinit Sahni <[REDACTED]>  
**Subject:** Re: Biotech Update... [C]  
**Date:** Thu, 08 May 2014 18:23:51 +0000  
**Inline-Images:** unnamed; unnamed(1); unnamed(2); unnamed(3); unnamed(4); unnamed(5); unnamed(6); unnamed(7); unnamed(8); unnamed(9)

Classification: Confidential

Jeffrey -

Updating you on your biotech basket because most of the names are struggling to rebound from the recent rotational sell-off, exception is GILD which has good valuation support, showed a strong earnings beat, and is back up to ~\$79.36 (your avg cost is \$79.41). FMI reported earnings after the close yesterday, which were inline but guidance was on the low end. Stock has sold off 15% (down to ~\$24 currently from from a high of \$30 yesterday). Please find your updated P/L below. Included SGMO chart - that company reported a moderately better quarter on Tuesday evening, hence the 3% uptick and several positive reports from the competitors across the Street.

As of 5/8/14 2:10 pm		PX_LAST						
Description	Trade Date	Quantity	Current Price	Unit Cost	Market Value	Current Total Cost	Unrealized G/L	
SANGAMO BIOSCIENCES	5/28/2013	50,000.00	\$ 12.17	\$ 8.44	\$ 608,500.00	422,214.00	\$ 186,286.00	
BIOGEN	2/14/2012	2,095.00	\$ 285.28	\$ 119.55	\$ 597,661.60	250,454.95	\$ 347,206.65	
FOUNDATION MEDICINE	1/13/2014	25,000.00	\$ 24.13	\$ 27.51	\$ 603,250.00	687,663.50	\$ (84,413.50)	
GILEAD SCIENCES INC	Multiple	8,100.00	\$ 79.36	\$ 79.41	\$ 642,816.00	643,204.00	\$ (388.00)	
					<b>Total Biotech</b>	<b>\$ 2,452,227.60</b>	<b>\$ 2,003,536.45</b>	<b>\$ 448,691.15</b>
ARIAD PHARMACEUTICALS	Multiple	16,535.00	\$ 6.76	\$ 17.60	\$ 111,776.60	290,997.40	\$ (179,220.80)	

Source: Bloomberg and Pershing LLC as of 5/8/14



**From:** Tazia Smith/db/dbcom  
**To:** jeevacation@gmail.com,  
**Cc:** Nav Gupta/db/dbcom@DBEMEA, Paul Morris, [REDACTED]  
**Date:** 04/22/2014 04:16 PM  
**Subject:** Re: Biotech Update... Gilead beat, shares halted [C]

Classification: Confidential

Jeffrey - sure you see this, just making sure, Gilead shares are halted in the after-market following a significant top and bottom-line earnings beat (\$1.48 vs \$0.92 cons eps, \$5bn on the topline vs. expectations of \$3.96bn) as you know, you're long 8100 shares at an average price of \$79.41, stock closed today at \$72.86, just reported.

Shares expected to re-open at 4:30pm



From: [Redacted]  
 To: [Redacted]  
 Cc: [Redacted]  
 Date: 06/02/2014 05:42 PM  
 Subject: Biotech Update... [C]

Classification: Confidential

Jeffrey -

Biotech forming a base to some extent (strong market backdrop, clearly) - you're up \$906k on your basket excluding the Ariad (outlier due to [Redacted] prospects vs. group drivers) 1-mo price history charts below.

As of 4/2/14 3:27 pm

Description	Trade Date	Quantity	Current Price	Unit Cost	Market Value	Current Total Cost	Unrealized G/L	
SANGAMO BIOSCIENCES	5/28/2013	50,000.00	\$ 17.51	\$ 8.44	\$ 875,500.00	422,214.00	\$ 453,286.00	
BIOGEN	2/14/2012	2,095.00	\$ 308.71	\$ 119.55	\$ 646,747.45	250,454.95	\$ 396,292.50	
FOUNDATION MEDICINE	1/13/2014	25,000.00	\$ 31.62	\$ 27.51	\$ 790,500.00	687,663.50	\$ 102,836.50	
GILEAD SCIENCES INC	Multiple	8,100.00	\$ 73.79	\$ 79.41	\$ 597,699.00	643,204.00	\$ (45,505.00)	
					<b>Total Biotech</b>	<b>\$ 3,043,139.83</b>	<b>\$ 2,294,533.85</b>	<b>\$ 906,910.00</b>
ARIAD PHARMACEUTICALS	Multiple	16,535.00	\$ 8.03	\$ 17.60	\$ 132,693.38	290,997.40	\$ (158,304.03)	

SGMO 1mo Price History



BIIB 1mo Price History



**GILD 1mo Price History**



**FMI 1mo Price History**





**Tazia Smith**

Director | Key Client Partners - US

DB Securities Inc  
Deutsche Asset & Wealth Management  
345 Park Avenue, 10154-0004 New York, NY, USA  
Tel. +1(212)454-2889  
Fax +1(846)257-3131  
Mobile +1 (917)327-4107  
Email [REDACTED]

*Passion to Perform*

---  
This communication may contain confidential and/or privileged information. If you are not the intended recipient (or have received this communication in error) please notify the sender immediately and destroy this communication. Any unauthorized copying, disclosure or distribution of the material in this communication is strictly forbidden.

Deutsche Bank does not render legal or tax advice, and the information contained in this communication should not be regarded as such.